London Genetics

The deal gives Quintiles access to PGT’s genomic data-analysis technology, and is in line with Quintiles' ongoing efforts to expand its pharmacogenomics research capabilities.

After inking a similar deal with Dako earlier in the month, Quintiles announced this week that it would collaborate with pharmacogenetics firm London Genetics to provide personalized medicine services to drug developers. Financial terms of the deal were not disclosed.

The companies will provide biomarker and assay development services and consulting to biopharmas through a new alliance.

A grant from the UK's East Midlands Development Agency will facilitate the search for a biomarker to personalize Astrimmune's pancreatic cancer vaccine.

The biomarkers will be used to predict clinical response to an Astrimmune vaccine, which induces antibody production against gastrin.

According to the partners, the software, which is based on Diaceutics Fusion platform, will help commercial companies build biomarker hypotheses, request expressions of interest, and prepare proposals for clinical development.

The new software, which the firms plan to launch next year, is based on the Diaceutics Fusion platform, a personalized medicine planning application designed for targeted therapy development teams, and the London Genetics Biomarker Pathway platform.

The software, which is anticipated to be launched next year, will allow research teams to build biomarker hypotheses, request expressions of interest and prepare proposals for clinical development.

Pairings

Premium

Stephen DeCherney, Munir Pirmohamed

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.